We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag
Read MoreHide Full Article
On Jun 28, we issued an updated research report on Elmsford, NY-based BioScrip, Inc. . The company is a leading Infusion Service provider and strives to deliver cost-effective programs to patients. The stock currently has a Zacks Rank #3 (Hold).
Over the last one month, BioScrip has been trading above the Zacks categorized Medical - Outpatient and Home Healthcare industry. The stock has gained 44.2%, way higher than the 5.1% gain of the broader industry. BioScrip currently operates in a lucrative market with favorable dynamics and solid fundamentals. In particular, market factors, developing patient management technologies and an aging U.S. population are enhancing opportunities for home health service providers like BioScrip.
We are encouraged by the company’s progress on its new multi-faceted CORE plan to improve its financial position. The plan involves identifying and executing strategies to accelerate core revenue growth, mix, drive operational efficiency, improve revenue collection and increase employee effectiveness.
Meanwhile, management has been recording consistent growth in its core Infusion Services business where it has a strong presence and enjoys competitive advantage. This is on account of strong organic growth particularly in chronic, nutrition and other therapies. To strengthen the business, the company has executed quite a few takeovers and divestitures in recent times. The company is currently on track to achieve the previously announced $17 million in Home Solutions synergies and other incremental annualized cost reductions of $23–$25 million by the end of 2017.
Of late, restricted spending by many states on Medicare raises apprehension over BioScrip’s prospects. The reason behind the cutbacks is slow revenue growth and rising Medicaid concerns. The Cures Act legislation passed in Dec 2016 has resulted in a significant reduction in Medicare reimbursement rates on certain drugs effective Jan 1. Hence, BioScrip’s 2017 guidance lacks luster as it takes the estimated adverse effect of the Cures Act legislation into account.
Moreover, the healthcare industry is highly competitive. BioScrip’s competitors include large and well-established companies that have higher financial, marketing and technological resources.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added almost 30.4% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 21.9% over the last three months.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has added roughly 12.9% over the last three months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag
On Jun 28, we issued an updated research report on Elmsford, NY-based BioScrip, Inc. . The company is a leading Infusion Service provider and strives to deliver cost-effective programs to patients. The stock currently has a Zacks Rank #3 (Hold).
Over the last one month, BioScrip has been trading above the Zacks categorized Medical - Outpatient and Home Healthcare industry. The stock has gained 44.2%, way higher than the 5.1% gain of the broader industry. BioScrip currently operates in a lucrative market with favorable dynamics and solid fundamentals. In particular, market factors, developing patient management technologies and an aging U.S. population are enhancing opportunities for home health service providers like BioScrip.
We are encouraged by the company’s progress on its new multi-faceted CORE plan to improve its financial position. The plan involves identifying and executing strategies to accelerate core revenue growth, mix, drive operational efficiency, improve revenue collection and increase employee effectiveness.
Meanwhile, management has been recording consistent growth in its core Infusion Services business where it has a strong presence and enjoys competitive advantage. This is on account of strong organic growth particularly in chronic, nutrition and other therapies. To strengthen the business, the company has executed quite a few takeovers and divestitures in recent times. The company is currently on track to achieve the previously announced $17 million in Home Solutions synergies and other incremental annualized cost reductions of $23–$25 million by the end of 2017.
Of late, restricted spending by many states on Medicare raises apprehension over BioScrip’s prospects. The reason behind the cutbacks is slow revenue growth and rising Medicaid concerns. The Cures Act legislation passed in Dec 2016 has resulted in a significant reduction in Medicare reimbursement rates on certain drugs effective Jan 1. Hence, BioScrip’s 2017 guidance lacks luster as it takes the estimated adverse effect of the Cures Act legislation into account.
Moreover, the healthcare industry is highly competitive. BioScrip’s competitors include large and well-established companies that have higher financial, marketing and technological resources.
Key Picks
A few better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Inogen sports a Zacks Rank #1(Strong Buy), while Align Technology and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added almost 30.4% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 21.9% over the last three months.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has added roughly 12.9% over the last three months.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>